



DAVID COOKSEY
MEDICAL RESEARCH STRATEGY

IMPACT ON THE UK ECONOMY

BIGT2R



MEDICAL RESEARCH PRIORITIES
WHY DO RESEARCH?

- ❑ KNOWLEDGE FOR ITS OWN SAKE
- ❑ PATIENT BENEFIT
- ❑ ECONOMIC BENEFIT
- ❑ ROLE IN BRITISH ECONOMY

BIGT2R



MEDICAL RESEARCH PRIORITIES

3 REPORTS – TOO LITTLE PROGRESS

- 2003 BIGT - UKCRC
- 2006 COOKSEY REVIEW - OSCHR/NIHR
- 2009 BIGT2R - ? OLS ?

BIGT2R



MEDICAL RESEARCH PRIORITIES

BIGT2R

- FINANCE & TAXATION
- REGULATION
- TRAINED WORKFORCE
- BIOPROCESSING CAPABILITY
- NHS – ASSET OR LIABILITY

BIGT2R



MEDICAL RESEARCH PRIORITIES

THE FRACTURED CHAIN

- ❑ ECONOMIC MODEL IS BROKEN
- ❑ DRUG DEVELOPMENT PATHWAY
UNSUSTAINABLE
- ❑ NHS UPTAKE OF NEW THERAPIES

BIGT2R



MEDICAL RESEARCH PRIORITIES

INVESTMENT IN DRUG DEVELOPMENT

- ❑ BLOCKBUSTER → PERSONALISED MEDICINE
- ❑ LENGTHENING TIMESCALES
- ❑ COST OF LARGE MOLECULES
- ❑ PROBABILITY OF SUCCESS

BIGT2R



MEDICAL RESEARCH PRIORITIES

CAN WE CHANGE THE MODEL?

- ❑ BALANCE RISK & REWARD
- ❑ NEW DRUG DEVELOPMENT PATHWAY
ROLE OF IT AND NHS
- ❑ ROLE OF NICE
- ❑ PEOPLE CAPABILITY & INCENTIVES
- ❑ PROCESS CAPABILITY
- ❑ NHS AS A CUSTOMER

BIGT2R



MEDICAL RESEARCH PRIORITIES

OBJECTIVES FULFILLED

- ❑ CONTINUE TO BUILD RESEARCH BASE
- ❑ INCENTIVES FOR CLINICAL RESEARCH
- ❑ NHS TO BECOME AN INNOVATION HUB
- ❑ DEVELOP PRODUCTS IN UK
- ❑ LIFE SCIENCES: A CORE ECONOMIC DRIVER

BIGT2R